Stevanato Group S.p.A. (STVN)

Market Cap	5.36B
Revenue (ttm)	1.22B
Net Income (ttm)	127.92M
Shares Out	272.90M
EPS (ttm)	0.48
PE Ratio	41.36
Forward PE	33.45
Dividend	$0.06 (0.30%)
Ex-Dividend Date	Jun 4, 2024

Volume	422,834
Open	19.64
Previous Close	19.62
Day's Range	19.44 - 19.97
52-Week Range	16.56 - 34.73
Beta	0.58
Analysts	Buy
Price Target	29.33 (+49.26%)
Earnings Date	Nov 5, 2024

About STVN

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines,...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 16, 2021
• Employees: 5,634
• Stock Exchange: NYSE
• Ticker Symbol: STVN
• Website: https://www.stevanatogroup.com

Financial Performance

In 2023, Stevanato Group's revenue was 1.09 billion, an increase of 10.34% compared to the previous year's 983.68 million. Earnings were 145.63 million, an increase of 1.95%.

Financial numbers in EUR

Analyst Forecast

According to 3 analysts, the average rating for STVN stock is "Buy." The 12-month stock price forecast is $29.33, which is an increase of 49.26% from the latest price.

Price Target

$29.33

(49.26% upside)

Analyst Consensus: Buy